Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women
Abstract
1. Introduction
2. Material and Methods
3. Results and Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Coutinho, E.M.; Da Silva, A.R. Contraceptive effectiveness of Silastic implants containing the progestin R-2323. Contraception 1975, 11, 625–635. [Google Scholar] [CrossRef] [PubMed]
- Schindler, A.E.; Campagnoli, C. Classification and pharmacology of progestins. Maturitas 2008, 61, 171–180. [Google Scholar] [CrossRef]
- Słopień, R.; Męczekalski, B. Aromatase inhibitors in the treatment of endometriosis. Menopausal Rev. 2016, 1, 43–47. [Google Scholar] [CrossRef]
- Coutinho, E.M.; Azadian-Boulanger, G. Treatment of fibrocystic disease of the breast with gestrinone, a new trienic synthetic steroid with anti-estrogen, anti-progesterone properties. Int. J. Gynecol. Obstet. 1984, 22, 363–366. [Google Scholar] [CrossRef]
- Ciou, H.H.; Lee, T.H. Repurposing gestrinone for tumor suppressor through P21 reduction regulated by JNK in gynecological cancer. Transl. Res. 2022, 243, 21–32. [Google Scholar] [CrossRef]
- Tostes, F. Effects of Exposing Different Cell Lines to Gestrinone. Master’s Thesis, Multicenter Postgraduate Program in Biochemistry and Molecular Biology—Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 2020. [Google Scholar]
- American Cancer Society. About Breast Cancer 2022. Available online: https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html (accessed on 20 February 2024).
- Donovitz, G.; Cotten, M. Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study. Eur. J. Breast Health 2021, 17, 150–156. [Google Scholar] [CrossRef] [PubMed]
- Glaser, R.; Dimitrakakis, C. Rapid response to breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: Neoadjuvant hormone therapy in breast cancer. Menopause 2014, 21, 673–678. [Google Scholar] [CrossRef] [PubMed]
- Glaser, R.; Dimitrakakis, C. Testosterone and breast cancer prevention. Maturitas 2015, 82, 291–295. [Google Scholar] [CrossRef]
- Ando, S.; De Amicis, F. Breast Cancer: From Estrogen To Androgen Receptor. Mol. Cell Endocrinol. 2002, 193, 121–128. [Google Scholar] [CrossRef]
- Colditz, G.A.; Hankinson, S.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1999, 332, 1589–1593. [Google Scholar] [CrossRef]
- Sitruk-Ware, R. New progestogens: A review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004, 21, 865–883. [Google Scholar] [CrossRef] [PubMed]
- Zhu, Y.; Zhang, T. Gestrinone inhibits growth of human uterine leiomyoma may relate to activity regulation of ERα, Src and P38 MAPK. Biomed. Pharmacother 2012, 66, 569–577. [Google Scholar] [CrossRef] [PubMed]
- Gestrinone Italian Study Group. Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertil Steril 1996, 66, 911–919. [Google Scholar] [CrossRef] [PubMed]
- Magri, B.; Viganò, P. Comparative Effect of the Calcium Antagonist Verapamil and the Synthetic Steroids Gestrinone and Danazol on Human Monocyte Phagocytosis in vitro. Gynecol. Obstet. Investig. 1997, 43, 6–10. [Google Scholar] [CrossRef] [PubMed]
- Eshre, Guideline Endometriosis. 2 February 2022. Available online: https://www.Eshre.Eu/Guideline/Endometriosis (accessed on 14 September 2024).
- Coutinho, E.M.; Gonçalves, M.T. Long-Term Treatment of Leiomyomas with Gestrinone. Fertil Steril 1989, 51, 939–946. [Google Scholar] [CrossRef] [PubMed]
- Alvarez, F.; Robertson, D.N. Comparative clinical trial of the progestins R-2323 and levonorgestrel administered by subdermal implants. Contraception 1978, 18, 151–162. [Google Scholar] [CrossRef]
- Renke, G.; Callizo, C. Clinical Approaches to Nestorone Subdermal Implant Therapy in Women′s Health. Biomedicines 2023, 11, 2586. [Google Scholar] [CrossRef]
- Sitruk-Ware, R.; Bonsack, B. Progress in progestin-based therapies for neurological disorders. Neurosci. Biobehav. Rev. 2021, 122, 38–65. [Google Scholar] [CrossRef]
- Tuazon, J.P.; Sitruk-Ware, R. Beyond contraception and hormone replacement therapy: Advancing Nestorone to a neuroprotective drug in the clinic. Brain Res. 2019, 1704, 161–163. [Google Scholar] [CrossRef]
- Dawood, M.Y.; Obasiolu, C.W. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am. J. Obstet. Gynecol. 1997, 176, 387–394. [Google Scholar] [CrossRef]
- Poojari, A.; Dev, K. Lipedema: Insights into Morphology, Pathophysiology, and Challenges. Biomedicines 2022, 10, 3081. [Google Scholar] [CrossRef] [PubMed]
- Renke, G.; Tostes, F. Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We? Pharmaceuticals 2023, 16, 619. [Google Scholar] [CrossRef] [PubMed]
- Baik, S.H.; Baye, F. Use of menopausal hormone therapy beyond age 65 years and its effects on women′s health outcomes by types, routes, and doses. Menopause 2024, 31, 363–371. [Google Scholar] [PubMed]
- Renke, G.; Kemen, E. Cardio-Metabolic Health and HRT in Menopause: Novel Insights in Mitochondrial Biogenesis and RAAS. Curr. Cardiol. Rev. 2023, 19, e060223213459. [Google Scholar] [CrossRef]
- Dinu, M.D.; Haj Hamoud, B. Endometriosis in Menopausal Women-A New Age Is Coming? Literature Review. Life 2024, 14, 485. [Google Scholar] [CrossRef]
- Cunningham, D.; Gazet, J.C. Oral gestrinone: A novel antiprogestin with no antitumor activity in endocrine-sensitive breast cancer. Cancer Treat Rep. 1987, 71, 1091–1092. [Google Scholar]
- Hornstein, M.D.; Gleason, R.E. A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis. Fertil Steril 1990, 53, 237–241. [Google Scholar] [CrossRef] [PubMed]
- Venturini, P.L.; Bertolini, S. Endocrine, metabolic, and clinical effects of gestrinone in women with endometriosis. Fertil Steril 1989, 52, 589–595. [Google Scholar] [CrossRef]
- Coutinho, E.M.; Azadian-Boulanger, G. Treatment of endometriosis by vaginal administration of gestrinone. Fertil Steril 1988, 49, 418–422. [Google Scholar] [CrossRef]
- Coutinho, E.M. Gestrinone in the treatment of myomas. Acta Obs. Gynecol. Scand. Suppl. 1989, 150, 39–46. [Google Scholar] [CrossRef]
- Coutinho, E.M.; Boulanger, G.A. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone. Am. J. Obs. Gynecol. 1986, 155, 761–767. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.X. Effect of mifepristone in the different treatments of endometriosis. Clin. Exp. Obs. Gynecol. 2016, 43, 350–353. [Google Scholar] [CrossRef]
- Fukuda, Y.; Tamura, S. Effects of gestrinone on serum lipid and lipoprotein levels in women with endometriosis. Nihon Sanka Fujinka Gakkai Zasshi 1989, 41, 577–584. [Google Scholar] [PubMed]
- De Souza Pinto, L.P.; Ferrari, G. Evaluation of Safety and Effectiveness of Gestrinone in the Treatment of Endometriosis: A Systematic Review and Meta-Analysis. Arch Gynecol. Obs. 2023, 307, 21–37. [Google Scholar] [CrossRef]
- Clinicaltrials.gov (Identifier NCT05570786). Available online: https://clinicaltrials.gov/study/NCT05570786?cond=gestrinone&rank=2 (accessed on 14 September 2024).
- Clinicaltrials.gov (Identifier NCT06543550). Available online: https://clinicaltrials.gov/study/NCT06543550?cond=gestrinone&rank=3 (accessed on 14 September 2024).
- Clinicaltrials.gov (Identifier NCT06402344). Available online: https://clinicaltrials.gov/study/NCT06402344?cond=gestrinone&rank=1 (accessed on 14 September 2024).
Progestin/Action | P4 | AG | E | AE | A | AA | GC | AM |
---|---|---|---|---|---|---|---|---|
Progesterone | + | + | − | + | − | +/− | + | + |
Gestrinone | +/− | + | − | + | + | − | + | + |
Nestorone | + | + | − | +/− | − | +/− | − | − |
Dihydrogesterone | + | − | − | + | − | +/− | − | +/− |
Medrogesterone | + | + | − | + | − | +/− | − | − |
Chlormadionona Acetate | + | + | − | + | − | + | + | − |
Cyproterona Acetate | + | + | − | + | − | ++ | + | − |
Megestrol Acetate | + | + | − | + | +/− | + | + | − |
Medroxyprogesterone Acetate | + | + | − | + | +/− | − | + | − |
Nomegestrol Acetate | + | + | − | + | − | +/− | − | − |
Promegestone | + | + | − | + | − | − | − | − |
Trimegestone | + | + | − | + | − | +/− | − | +/− |
Drosperinone | + | + | − | + | − | + | − | + |
Nortiesteronae | + | + | + | +/− | + | − | − | − |
Linestrenol | + | + | + | + | + | − | − | − |
Norethisterone | + | + | + | + | +/− | − | − | − |
Levonorgestrel | + | + | − | + | + | − | − | − |
Norgestimata | + | + | − | + | + | − | − | − |
3-Ceto-desogestrel | + | + | − | + | + | − | − | − |
Gestoden | + | + | − | + | + | − | + | + |
Dienogest | + | + | − | +/− | − | + | − | − |
Author(s), Year, Reference Number | Route | Gestrinone Protocol | Characteristic of Study/Participants | Applicability |
---|---|---|---|---|
Coutinho et al. (1975) [1] | Silastic subdermic Implant | 30–40 mg (6 to 12 months) | Prospective study (531 pre-menopausal women) | Contraception effectiveness |
Coutinho et al. (1984) [4] | Oral | 5 mg twice a week (3 to 9 months) | Prospective study (28 women diagnosed with breast fibrocystic disease) | Fibrocystic disease of the breast |
Ciou et al. (2022) [5] | - | - | Retrospective study (8330 endometriosis patients) | Anticancer efficacy of gestrinone |
Gestrinone Italian Study Group (1996) [15] | Oral | 2.5 mg twice a week versus leuprolide acetate 3.75 mg depot injections every 4 weeks | Randomized, double-blind, multicenter study (25 endometriosis patients with moderate or severe pelvic pain) | Pelvic pain associated with endometriosis |
Coutinho et al. (1989) [18] | Oral/Vaginal | Oral 2.5 mg of gestrinone three times weekly Oral 5.0 mg twice weekly Vaginal route tablets containing 5 mg (24 months) | Randomized, prospective study (100 women with leiomyomas) | Reduction in uterine volume |
Alvarez et al. (1978) [19] | Silastic subdermic Implant | Gestrinone 30 mg versus levonorgestrel 30 mg | Prospective study (100 pre-menopausal women) | Contraception effectiveness |
Dawood et al. (1997) [23] | Oral | 1.25 mg or 2.5 mg twice a week (24 weeks) | Randomized, double-blind, prospective study (11 patients given gestrinone | Treatment of endometriosis |
Cunningham et al. (1987) [29] | Oral | 2.5 mg every 3 days | Prospective study (15 patients with locally advanced or metastatic breast cancer) | Anticancer efficacy of gestrinone |
Hornstein et al. (1990) [30] | Oral | 1.25 mg twice weekly 2.5 mg twice weekly | Randomized, double-blind, prospective study (12 women with endometriosis | Treatment of endometriosis |
Venturini et al. (1989) [31] | Oral | 2.5 mg twice weekly (6 months) | Prospective study (11 women with mild or moderate endometriosis) | Treatment of endometriosis |
Coutinho et al. (1988) [32] | Vaginal | 2.5 mg tablets weekly 2.5 mg twice a week three 2.5 mg tablets weekly (6 to 8 months) | Prospective study (110 patients with endometriosis). | Treatment of endometriosis |
Coutinho et al. (1989) [33] | Oral/Vaginal | 2.5–5 mg (orally or by vaginal pessary), two or three times weekly (6 months) | Prospective study (300 women with uterine myomas) | Treatment of uterine myomas |
Coutinho et al. (1986) [34] | Oral/Vaginal | Oral 5 mg twice weekly Oral 2.5 mg capsules three times weekly Vaginal 2.5 mg tablets three times weekly (4 to 13 months) | Prospective study (97 women, with uterine leiomyomas) | Treatment of uterine leiomyomas |
Zhang et al. (2016) [35] | Oral | Oral 2.5 mg twice a week versus mifepristone 12.5 mg daily | Randomized controlled prospective study (65 women with endometriosis) | Treatment of endometriosis |
Fukuda et al. (1989) [36] | Oral | 5 or 10 mg weekly (4 to 6 months) | Prospective study (12 women with endometriosis) | Effect on serum lipid and lipoprotein levels in women with endometriosis |
De Souza Pinto et al. (2023) [37] | - | - | Systematic review and meta-analysis of 16 studies involving 1286 women | Treatment of endometriosis |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Renke, G.; Antunes, M.; Sakata, R.; Tostes, F. Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women. Pharmaceuticals 2024, 17, 1248. https://doi.org/10.3390/ph17091248
Renke G, Antunes M, Sakata R, Tostes F. Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women. Pharmaceuticals. 2024; 17(9):1248. https://doi.org/10.3390/ph17091248
Chicago/Turabian StyleRenke, Guilherme, Mariana Antunes, Renato Sakata, and Francisco Tostes. 2024. "Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women" Pharmaceuticals 17, no. 9: 1248. https://doi.org/10.3390/ph17091248
APA StyleRenke, G., Antunes, M., Sakata, R., & Tostes, F. (2024). Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women. Pharmaceuticals, 17(9), 1248. https://doi.org/10.3390/ph17091248